Abstract
The story of anti-obesity drugs as agents promoting excess body weight reduction is a long one yet associated with little success. While the broadest indications and least limitations apply to the orlistat, a lipase blocker; the already limited use of phentermine virtually stopped after it had been moved to the "opiate" category.
The new naltrexone/bupropion combination holds promise in comprehensive modulation of food intake including a reward mechanism; however, the body of experience with the combination is still limited. The spectrum of anti-obesity drugs is likely to expand after the inclusion of some antidiabetics, liraglutide and gliflozins in particular.
The fate of active substances currently under investigation is difficult to predict.